Zalcitabine-13C,15N2
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for complete information.
Zalcitabine-13C,15N2 Product Information
Zalcitabine-13C,15N2 is listed under Stable Isotopes and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-96335.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Zalcitabine-13C,15N2
CAT No.
CS-T-96335
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C813CH13N15N2O3
Molecular Weight
214.2
Category
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for complete information.
Description
Regulatory Description
Zalcitabine-13C,15N2 is supplied with detailed characterization data compliant with regulatory guideline. Zalcitabine-13C,15N2 can be used for analytical method development, method validation (AMV), Quality Control (QC), ANDA-related analytical work, and commercial pharmaceutical research applications.
Overview
Unlabeled Zalcitabine (Z140000) is a pyrimidine nucleoside analogue with antiviral activity.
Synonyms
Zalcitabine-13C,15N2
Application Notes
Unlabeled Zalcitabine (Z140000) is a pyrimidine nucleoside analogue with antiviral activity.
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.